At a glance
- Originator Aventis
- Class Anti-ischaemics; Small molecules
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Coronary artery restenosis
Most Recent Events
- 30 Jun 1995 Discontinued-Preclinical for Atherosclerosis in USA (Unknown route)
- 29 Jun 1995 Discontinued-Preclinical for Coronary artery restenosis in France (Unknown route)